Summary Annual Report 2013 in English
Today Vitrolife is publishing the Summary Annual Report 2013 in English. The Summary is attached to this press release.
The summary is a shorter document that summarises the main points in the Annual Report 2013, but is not a substitute for it and does not contain all the information needed to give as full an understanding of the Group’s performance, financial position and future prospects as is provided by the Annual Report 2013, which can be downloaded on www.vitrolife.com.
April 11, 2014
VITROLIFE AB (publ)
Queries should be addressed to:
Mikael Engblom, CFO, tel 46 31 721 80 14
Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on April 11, 2014 at 11:00 a.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
Vitrolife is an international medical device Group. Vitrolife Fertility product area develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes
Vitrolife has approximately 240 employees and the company's products are sold in almost 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: firstname.lastname@example.org. Website: www.vitrolife.com/